These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 32910283)

  • 1. Between-Batch Bioequivalence (BBE): a Statistical Test to Evaluate In Vitro Bioequivalence Considering the Between-Batch Variability.
    Bodin J; Liandrat S; Kocevar G; Petitcolas C
    AAPS J; 2020 Sep; 22(5):119. PubMed ID: 32910283
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Performance of the Population Bioequivalence (PBE) Statistical Test with Impactor Sized Mass Data.
    Chen S; Morgan B; Beresford H; Burmeister Getz E; Christopher D; Långström G; Strickland H; Wiggenhorn C; Lyapustina S
    AAPS PharmSciTech; 2019 Aug; 20(7):296. PubMed ID: 31444601
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Novel Simulation-Based Approach for Comparing the Population Against Average Bioequivalence Statistical Test for the Evaluation of Nasal Spray Products on Spray Pattern and Droplet Size Distribution Parameters.
    Grmaš J; Lužar-Stiffler V; Dreu R; Injac R
    AAPS PharmSciTech; 2019 Jan; 20(1):38. PubMed ID: 30604193
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Performance of the Population Bioequivalence (PBE) Statistical Test Using an IPAC-RS Database of Delivered Dose from Metered Dose Inhalers.
    Morgan B; Chen S; Christopher D; Långström G; Wiggenhorn C; Burmeister Getz E; Beresford H; Hoffelder T; Acerbi D; Andrews S; Berry M; Dey M; Joshi K; McKenry M; Pertile M; Strickland H; Wilcox D; Lyapustina S
    AAPS PharmSciTech; 2018 Apr; 19(3):1410-1425. PubMed ID: 29435904
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Batch Selection via In Vitro/In Vivo Correlation in Pharmacokinetic Bioequivalence Testing.
    Burmeister Getz E; Carroll KJ; Mielke J; Jones B; Benet LZ
    AAPS PharmSciTech; 2021 Aug; 22(7):224. PubMed ID: 34410534
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Population and individual bioequivalence: lessons from real data and simulation studies.
    Zariffa NM; Patterson SD
    J Clin Pharmacol; 2001 Aug; 41(8):811-22. PubMed ID: 11504268
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cascade Impactor Equivalence Testing: Comparison of the Performance of the Modified Chi-Square Ratio Statistic (mCSRS) with the Original CSRS and EMA's Average Bioequivalence Approach.
    Kurumaddali A; Christopher D; Sandell D; Strickland H; Morgan B; Bulitta J; Wiggenhorn C; Stein S; Lyapustina S; Hochhaus G
    AAPS PharmSciTech; 2019 Jul; 20(6):249. PubMed ID: 31286316
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Performance of Multiple-Batch Approaches to Pharmacokinetic Bioequivalence Testing for Orally Inhaled Drug Products with Batch-to-Batch Variability.
    Burmeister Getz E; Carroll KJ; Christopher JD; Morgan B; Haughie S; Cavecchi A; Wiggenhorn C; Beresford H; Strickland H; Lyapustina S
    AAPS PharmSciTech; 2021 Aug; 22(7):225. PubMed ID: 34410557
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drilling down the bioequivalence assessment of topical antifungal products: Microstructure and release.
    Miranda M; Cardoso C; Pais AACC; Brown M; Vitorino C
    Eur J Pharm Biopharm; 2023 Apr; 185():94-106. PubMed ID: 36806630
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of bioequivalence for highly variable drugs with scaled average bioequivalence.
    Tothfalusi L; Endrenyi L; Arieta AG
    Clin Pharmacokinet; 2009; 48(11):725-43. PubMed ID: 19817502
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interchangeability between Generic and Reference Products: Limits of Average Bioequivalence Methodology.
    Lechat P
    Eur J Drug Metab Pharmacokinet; 2022 Nov; 47(6):777-787. PubMed ID: 35986193
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bioequivalence between innovator and generic tacrolimus in liver and kidney transplant recipients: A randomized, crossover clinical trial.
    Alloway RR; Vinks AA; Fukuda T; Mizuno T; King EC; Zou Y; Jiang W; Woodle ES; Tremblay S; Klawitter J; Klawitter J; Christians U
    PLoS Med; 2017 Nov; 14(11):e1002428. PubMed ID: 29135993
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PhRMA perspective on population and individual bioequivalence.
    Barrett JS; Batra V; Chow A; Cook J; Gould AL; Heller AH; Lo MW; Patterson SD; Smith BP; Stritar JA; Vega JM; Zariffa N
    J Clin Pharmacol; 2000 Jun; 40(6):561-70. PubMed ID: 10868305
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current Regulatory Standpoint on Evaluating the Bioequivalence of Different Classes of Generic Drugs - Is the Evaluation in the Right Direction?
    Micheal F; Sayana M; Motial BM
    Curr Drug Metab; 2019; 20(10):835-844. PubMed ID: 31589117
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trapezoid bioequivalence: A rational bioavailability evaluation approach on account of the pharmaceutical-driven balance of population average and variability.
    Soufsaf S; Nekka F; Li J
    CPT Pharmacometrics Syst Pharmacol; 2022 Apr; 11(4):482-493. PubMed ID: 35303757
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Topical bioequivalence: Experimental and regulatory considerations following formulation complexity.
    Miranda M; Veloso C; Brown M; C Pais AAC; Cardoso C; Vitorino C
    Int J Pharm; 2022 May; 620():121705. PubMed ID: 35358644
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diving into Batch-to-Batch Variability of Topical Products-a Regulatory Bottleneck.
    Miranda M; Cova T; Augusto C; Pais AACC; Cardoso C; Vitorino C
    Pharm Res; 2020 Oct; 37(11):218. PubMed ID: 33037479
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alternative confidence intervals for the assessment of bioequivalence in four-period cross-over designs.
    Quiroz J; Ting N; Wei GC; Burdick RK
    Stat Med; 2002 Jul; 21(13):1825-47. PubMed ID: 12111892
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of Prescribability and Switchability by Using Multiple Bioequivalence Assessment Approaches.
    Micheal F; Sayana M; Prasad R; Motial BM
    Drug Metab Lett; 2021; 14(2):141-151. PubMed ID: 33745439
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro studies into establishing therapeutic bioequivalence of complex topical products: Weight of evidence.
    Miranda M; Volmer Z; Cornick A; Goody A; Cardoso C; Pais AACC; Brown M; Vitorino C
    Int J Pharm; 2024 May; 656():124012. PubMed ID: 38537923
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.